Colon Cancer News and Research

Latest Colon Cancer News and Research

Long term decline in hemoglobin may announce onset of colorectal cancer

Anemia, a common blood disorder characterized by low hemoglobin levels, has long been associated with those suffering from colorectal cancer. But researchers at Tel Aviv University have discovered that, more than a symptom of active disease, low hemoglobin levels can actually indicate a potential for colon cancer years before it's diagnosed.

4 Aug 2010

Adequate calcium intake maintains optimum bone mass

A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.

31 Jul 2010

ACS CAN report finds nearly half of all states falling short on legislative solutions to prevent, fight cancer

Nearly half of all states are falling short on legislative solutions to prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN). However, despite budget crises in several states, some state lawmakers still made positive progress in the fight against a disease that will kill an estimated 569,000 people in the United States this year.

29 Jul 2010

Exact Sciences reports total revenues of $1.3M for second-quarter 2010

Exact Sciences Corp. today announced its financial results for the second quarter ended June 30, 2010.

28 Jul 2010

MabCure's MAbs 94% accurate in identifying ovarian cancer

Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.

28 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

LCA survey sheds more light on why support for lung cancer people remains low

A national survey announced today by Lung Cancer Alliance, sheds more light on why support for people affected by lung cancer remains low. The poll indicates Americans are more likely to view lung cancer as "hopeless" and "untreatable" when compared with a diagnosis of breast or colon cancer. In addition, 26% of Americans believe lung cancer is largely "self-inflicted."

23 Jul 2010

BioTime announces 21 new stem cell products for sale

BioTime, Inc. announced today that on August 1, 2010 the Company will be offering for sale 21 new stem cell products for research use only. These products will include the novel stem cell lines: E120 expressing the gene LGR5 useful in colon cancer drug discovery, EN16, T43, RAD20.5, RA-SKEL8, SM22, and Z1, full properties of which will be disclosed on product launch, along with differentiation kits and media for the culture of each line.

22 Jul 2010

Researchers block stress responses in cancer surgery patients

Cancer surgery wreaks havoc on a body's immune system and stress hormones exacerbate the problem. As a result, about half of those who undergo surgery for tumor removal experience a recurrence of cancer in the same region or other parts of the body.

22 Jul 2010

GE, MSKCC launch colon cancer study

A team of scientists at GE Global Research, the technology development arm for the GE, has launched a study with Memorial Sloan-Kettering Cancer Center, (MSKCC) one of the world's premier cancer centers, to better understand the early stages of colon cancer. The goal is to yield new insights that improve treatment selection and outcomes for cancer patients in the future.

22 Jul 2010

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

According to a Food and Drug Administration (FDA) advisory committee’s (The Oncology Drugs Advisory Committee, or ODAC) recommendation this Tuesday, the marketing approval of the popular breast cancer drug, Avastin or Bevacizumab should be withdrawn.

21 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Combined technologies offer promise for detecting colon cancer in women

A team led by a Northwestern University biomedical engineer has found that combining novel optical technologies with a common colon cancer screening test may allow doctors to more accurately detect the presence of colon cancer, particularly in women.

20 Jul 2010

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

17 Jul 2010

FDA can promote personalized medicine by identying gaps in laboratory operations: ACLA

The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation's leading clinical laboratories, says that the factors supporting this approach include the growing role that such tests play in clinical decision making, especially in the area of new advanced diagnostics that derive from the mapping of the human genome and help fulfill the promise of personalized medicine.

17 Jul 2010

Two-thirds of world's population are vitamin D-insufficient or deficient

Vitamin D surfaces as a news topic every few months. How much daily vitamin D should a person get? Is it possible to have too much of it? Is exposure to the sun, which is the body's natural way of producing vitamin D, the best option? Or do supplements suffice?

16 Jul 2010

The Samuel Waxman Cancer Research Foundation announces research grants totaling $1.54 million

The Samuel Waxman Cancer Research Foundation (SWCRF) has awarded 13 collaborative research grants and 3 individual research grants, totaling $1.54 million. The 16 grants represent a portion of the science grant program at the Foundation, which will award more than $2 million this year to cancer research.

14 Jul 2010

Fredericksburg Oncology invites participants for new metastatic melanoma clinical trial

Fredericksburg Oncology is now accepting patients for a new clinical trial supported by the National Cancer Institute (NCI) to evaluate treatment for metastatic (advanced stage) melanoma. The current trial, designed at the Mayo Clinic, combines chemotherapy with targeted molecular agents in an effort to improve control of this difficult disease, reports Dr. Frederick C. Tucker, Jr., who heads this practice.

13 Jul 2010

Co-morbidities, socioeconomic status impact survival rates in colorectal cancer

Blacks are surviving colorectal cancer at a significantly lower rate compared to whites and Asians due to co-morbidities and their socioeconomic status, according to research by epidemiologists at The University of Texas Health Science Center at Houston.

13 Jul 2010

OICR, CCO announce $6 million in funding for Health Services Research Program projects

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), and Dr. Terrence Sullivan, President and CEO of Cancer Care Ontario (CCO), announce $6 million in funding for projects in the Health Services Research Program (HSRP). The HSRP, conducted jointly between the OICR and CCO, will improve the delivery of cancer care throughout the province.

12 Jul 2010